ArticleiScience2025
SMCseeker: An attentive virtual screening model for antiviral discovery.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quantum computing applications in drug discovery.Briefings in bioinformatics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza virus, with high morbidity and mortality rates, is a global health threat. Traditional antiviral screenings are costly, whereas machine learning could enhance the effectiveness of antiviral drug discovery. Leveraging a large-scale, in-house antiviral dataset against H1N1, we developed a small molecule compound seeker (SMCseeker) framework for identifying highly active anti-H1N1 agents. Data augmentation and a multi-head attention mechanism were utilized to address the extreme data imbalance and enhance the generalization ability of the model. 18,093 structure-activity signatures after cleaning from 52,800 compounds were selected for training, with another 3,876 validation and 3,879 unseen data points to verify the model's generalization ability. H1N1-SMCseeker demonstrates stable performance on validation dataset, unseen dataset, and one experiment, with Positive Predictive Values (PPV) of 70.59%, 70.59%, and 70.65%, respectively. Therefore, H1N1-SMCseeker can effectively identify anti-H1N1 compounds. The SMCseeker framework could potentially be repurposed for discovering antivirals against other medically important viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.